p53 and HER-2/neu overexpression in ovarian borderline tumors

Gynecologic Oncology

Volumn 65, Issue 2, 1997, Pages 218-224

  Eltabbakh, Gamal H ^a,b   Belinson, Jerome L ^a   Kennedy, Alexander W ^a   Biscotti, Charles V ^a   Casey, Graham ^a   Tubbs, Raymond R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; OVARY TUMOR; PRIORITY JOURNAL; RECURRENCE RISK; TUMOR BIOPSY; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

EID: 0031149572     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4661     Document Type: Article

References (47)

1. Taylor H C. Malignant and semimalignant tumors of the ovary. Obstet Gynecol. 48:1929;204-230.
2. Acta Obstet Gynecol Scand. 50:1971;1-7.
3. S, F, Serov, R, E, Scully, L, H, Sobin, 1973, International Histologic Classification and Staging of Tumors: Histologic Typing of Ovarian Tumors, 37, 41, World Health Organization, Geneva, Switzerland.
4. Leake J F. Tumors of low malignant potential. Curr Opin Obstet Gynecol. 4:1992;81-85.
5. Kurman R J, Trimble C L. The behaviour of serous tumors of low malignant potential: are they ever malignant. J Gynecol Pathol. 12:1993;120-127.
6. Lawrence W D. The borderland between benign and malignant surface epithelial ovarian tumors. Cancer. 76:1995;2138-2142.
7. Link C J Jr, Kohn E, Reed E. The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: epidemiologic, pathologic, and molecular aspects. Gynecol Oncol. 60:1996;347-354.
8. Kupryjanczyk J, Thor A, Beauchamp T, Merritt V, Edegerton S M, Bell D A, Yandell D W. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA. 90:1993;4961-4965.
9. Henriksen R, Strang P, Wilander E, Backstrom T, Tribukait B, Oberg K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol. 53:1994;301-306.
10. Berchuck A, Kohler M F, Hopkins M P, Humphrey P A, Robboy S J, Rodriguez G C, Soper J T, Clarke-Pearson D L, Bast R C. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol. 52:1994;232-236.
11. Kupryjanczyk J, Bell D A, Yandell D W, Scully R E, Thor A D. p53 expression in ovarian borderline tumors and stage I carcinomas. Am J Clin Pathol. 102:1994;671-676.
12. Marcelli A R, Demopoulos R I, Goswami S, Mittal K R. Comparison of p53 and MIB1 expression in benign and borderline areas of ovarian serous tumors. Int J Gynecol Pathol. 15:1996;39-44.
13. Wertheim I, Muto M G, Welch W R, Bell D A, Berkowitz R S, Mok S C. p53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst. 86:1994;1549-1551.
14. Lee J H, Kang Y S, Park S Y, Kim B G, Lee E D, Lee K H, Park K B, Kavanagh J J, Wharton J T. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Cancer Genet Cytogenet. 85:1995;43-50.
15. Koshiyama M, Konishi I, Mandai M, Komatsu T, Yamamoto S, Nanbu K, Mori T.Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas: correlation with clinicopathology and sex steroid receptor status. Virchows Archiv. 425:1995;603-609.
16. Fujita M, Enomoto T, Inoue M, Tanizawa O, Ozaki M, Rice J M, Nomura T. Alteration of the p53 tumor suppressor gene occurs independently of k-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovaries. Jpn J Cancer Res. 85:1994;1247-1256.
17. Klemi P J, Takahashi S, Joensuu H, Narimatsu E, Mori M. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int J Gynecol Pathol. 13:1994;228-233.
18. Teneriello M G, Ebina M, Linnoila R I, Henry M, Nash J D, Park R C, Birrer M J. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 53:1993;3103-3108.
19. Kiyokawa T. Alteration of p53 in ovarian cancer: its occurrence and maintenance in tumor progression. Int J Gynecol Pathol. 13:1994;311-316.
20. Kappes S, Milde-Langosh K, Kressin P, Passlack B, Cockhorn-Dworniczak B, Rohlke P, Loning T. p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. Int J Cancer. 64:1995;52-59.
21. Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A, McGuire W L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:1987;177-182.
22. Singleton T P, Strickler J G. Clinical and pathologic significance of the c-erb-2 (HER-2/neu) oncogene. Pathol Annu. 27:1992;165-190.
23. Sakamoto H, Deng X, Ohtani K, Takami T, Takami M, Shirakawa T, Satoh K. ErbB-2, a c-erbB-2-coded protein, is expressed in metastatic cells of adenocarcinoma of endometrium, cervix and ovaries. Int J Gynecol Cancer. 5:1995;411-415.
24. Slamon D J, Godolphin W, Jones L A, Holt J A, Wong S G, Keith D E, Levin W J, Stuart S G, Udove J, Ullrich A, Press M F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
25. Berchuck A, Kamel A, Kerns W B, Olt G, Kinney R, Soper J T, Dodge D L, Clarke-Pearson D L, Marks P, McKenzie S, Yin S, Bast R C Jr. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50:1990;4087-4091.
26. Isola J, Viskorpi T, Holli K, Kallioniemi O-P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst. 84:1992;1109-1114.
27. Wright C, Mellon K, Johnsoton P, Lane D P, Harris A L, Horne C HW, Neal D E. Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer. 63:1991;967-970.
28. Kamel D, Paakko P, Nourva K, Vahkangas K, Soini Y. p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. J Pathol. 170:1993;67-72.
29. Bell D A, Scully R E. Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases. Hum Pathol. 21:1990;397-403.
30. Bergman C I, Hung M C, Weingerb R A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature. 319:1986;226-230.
31. Di Fiore P P, Pierce J H, Kraus M H, Segatto O, King C R, Aaronson S A. cerbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 237:1986;178-182.
32. Felip E, Campo J MD, Rubio D, Vidal M T, Colomer R, Bermejo B. Overexpression of c-erbB-2 in epithelial ovarian cancer. Cancer. 75:1995;2147-2152.
33. Rubin S C, Finstad C L, Wong G Y, Almadrones L, Plante M, Lloyd K O. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol. 168:1993;162-169.
34. Kacinski B M, Mayer A G, King B L, Carter D, Chambers S K. NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. Gynecol Oncol. 44:1992;245-253.
35. Haldane J S, Hird V, Hughes C M, Gullick W J. c-erbB-2 oncogene expression in ovarian cancer. J Pathol. 162:1990;231-237.
36. Singleton T P, Perrone T, Oakley G, Niehans G A, Carson L, Cha S S, Strickler J G. Activation of c-erbB-2 and prognosis in ovarian carcinoma: comparison with histologic type, grade, and stage. Cancer. 73:1994;1460-1466.
37. Guterson B A, Gelber R D, Goldhirsch A, Price K N, Save-Soder-borgh J, Anbazhagan R, Styles J, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettleheim R, Neville A M, Burk K, Castiglione M, Collins J, Lindtner J, Senn H-J. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol. 10:1992;1049-1056.
38. Seidman J D, Frisman D M, Norris H J. Expression of HER-2/neu proto-oncogene in serous ovarian neoplasms. Cancer. 70:1990;2857-2860.
39. Medl M, Sevelda P, Czerwenka K, Dobianer K, Hanak H, Hruza C, Klein M, Leodolter S, Mullouer-Ertle S, Rosen A, Salzer H, Vavara N, Spona J. DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer. Gynecol Oncol. 59:1995;321-326.
40. Sasano H, Garrett C T, Wilkinson D S, Silverberg S, Comerford J, Hyde J. Protooncogene amplification and tumor ploidy in human ovarian neoplasms. Hum Pathol. 21:1990;382-391.
41. Hung M-C, Zhang X, Yan D-H, Zhang H-Z, He G-P, Zhang T-Q, He G-P, Zhang T-Q, Shi D-R. Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. Cancer Lett. 61:1992;95-103.
42. Huettner P C, Carney W P, Naber S P, Delellis R A, Membrino W, Wolfe H J. Neu oncogene expression in ovarian tumors: a quantitative study. Mod Pathol. 5:1992;250-256.
43. Levine A J, Momand J, Finlay C A. The p53 tumor suppressor gene. Nature. 351:1991;453-456.
44. Kupryjanczyl J, Bell D A, Dimeo D, Beauchamp R, Thor A D, Yandell D W. p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol. 26:1995;387-392.
45. Momand J, Zambetti G P, Olson D C, George D, Levine A J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
46. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 8:1993;307-318.
47. Singleton T P, Niehans G A, Gu F, Litz C E, Hagen K, Qiu Q, Kiang D T, Strickler J G. Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol. 23:1992;1141-1150.